Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of BMN 270 in adults with hemophilia A and active or prior FVIII inhibitors
MOH_2023-11-16_012701Phase 2Not yet recruiting
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jul 2023
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of valoctocogene roxaparvovec in hemophilia A (2 arms), sponsored by BioMarin Pharmaceutical Inc. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
valoctocogene roxaparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on MOH_2023-11-16_012701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-16_012701.